ArticleFrontiers in pharmacology2026
Integrating pretreatment CT radiomics and circulating tumor cells using machine learning to predict survival in hepatocellular carcinoma.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunotherapy has shown promising potential in the treatment of advanced hepatocellular carcinoma (HCC). This study aimed to establish and validate a multimodal prognostic model based on clinical variables, CT radiomics, and circulating tumor cell (CTC) counts for survival prediction in advanced HCC. Methods: Pretreatment CT images and baseline clinical data were collected from patients with advanced HCC. Radiomic features were extracted from CT images, and candidate machine learning pipelines were screened to derive an optimal radiomics signature. Clinical and biomarker variables associated with overall survival were identified using Cox regression analyses and incorporated into prognostic nomograms. Model discrimination, calibration, and clinical utility were evaluated in internal and external validation cohorts. Results: The addition of immunotherapy was associated with improved prognosis in patients with advanced HCC. Among the prognostic models, the Clinical-Radiomic-CTC nomogram outperformed the Clinical-Radiomic nomogram, showing a higher concordance index (0.789) and higher area under the receiver operating characteristic curves (AUCs) for 1-, 2-, and 3-year OS (0.889, 0.771, and 0.838, respectively). Conclusion: Machine learning models integrating radiomics and CTCs provided robust individualized prognostic prediction, supporting risk stratification and clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.